Search
ASGCT 2026: Ascidian Therapeutics is presenting initial human safety data from its RNA exon editing platform in a Stargardt disease trial
CSO Robert Bell describes the advantages of RNA exon editing he sees over DNA editing, and walks us through the safety data. With that in hand, which was in adult patients, the company is moving forward in pediatric patients. Coverage brought to you by
3 days ago
Ascidian Therapeutics' CEO discusses today's collaboration with Roche on the company's RNA exon editing technology for neurological conditions
Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA...
Jun 18, 2024
Ascidian presented NHP and human retinal explant data at #ASGCT2024 suggesting proof of concept for its RNA exon editing approach
Head of research Robert Bell described the preclinical data in a Stargardt disease model that has led to an IND acceptance for this...
May 9, 2024
The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease
Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing
Jan 29, 2024
.png){kind=logo}
